BD SurePath Liquid Based Cytology


Take the sure path to detection

About BD SurePath


The BD SurePath brand includes a liquid-based Pap test that is a Health Canada licensed process intended for use in the screening and detection of cervical cancer, precancerous lesions and atypical cells.1 This process is a unique, proprietary cell enrichment process that eliminates nondiagnostically relevant cells and interfering substances for a clearer, easier-to-read slide. The BD SurePath Pap test standardises collection and ensures 100% of the collected sample is sent to the laboratory for processing. No diagnostic cells are discarded in the clinic, unlike those with "rinse and swish" systems, which on average can result in the loss of 37% of the collected sample during cell transfer.

Learn more about the BD SurePath liquid-based Pap test

BD SurePath liquid-based Pap test

The BD SurePath liquid-based Pap test helps detect disease with a more quality and easily read sample than possible with conventional Pap smears and other liquid-based cytology (LBC) tests. The BD SurePath test is shown to: 

  • Increase HSIL+ detection by 64.4% compared to the conventional Pap smear2
  • Significantly reduce unsatisfactory results vs other screening methods3
  • Better tolerate samples with potentially interfering substances such as blood, mucous and inflammatory cells4

Learn more


Not all products and services may be available in your area. Please contact a BD representative for more information.

References
  1. BD PrepStain slide processor: direct-to-vial study population [product insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2016.
  2. Fremont-Smith M, Marino J, Griffin B, Spencer L, Bolick D. Comparison of the Surepath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 102:269-279.
  3. Nygård JF, Sauer T, Nygård M, Skare GB, Thoresen S Ø. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11(2):70-76.
  4. Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007:35(3):148-153.

1000-BDW-CA-EN-01411

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.